Last reviewed 2026-04-23 · How we verify

G238

Salvat · Phase 3 active Small molecule

G238 is a small molecule that targets the [unknown] mechanism to treat [unknown] conditions.

At a glance

Generic name	G238
Sponsor	Salvat
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Unfortunately, there is limited information available about the exact mechanism of action of G238.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

G238 CI brief — competitive landscape report
G238 updates RSS · CI watch RSS
Salvat portfolio CI